HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced two abstracts were accepted and presented at World Allergy Congress (WAC), held December 1 – 3, 2023 in Bangkok, Thailand.

HENDERSON，Nev.-（BUSINESS WIRE）-Zura Bio Limited（纳斯达克股票代码：Zura）（“Zura Bio”），一家专注于开发免疫和炎症性疾病新药的多资产临床阶段生物技术公司，今天宣布两篇摘要被接受并于2023年12月1日至3日在泰国曼谷举行的世界过敏大会（WAC）上发表。

The abstracts highlight Zura Bio’s informative research for ZB-168, an anti-IL-7Rα monoclonal antibody with potential across a broad set of indications where the IL-7 or TSLP pathways may be involved, and ZB-880 (torudokimab), a fully human, high affinity monoclonal antibody that neutralizes IL-33 and also has potential for a broad range of indications..

摘要重点介绍了Zura Bio对ZB-168的信息研究，ZB-168是一种抗IL-7Rα单克隆抗体，可能涉及IL-7或TSLP途径的广泛适应症，ZB-880（torudokimab）是一种完全人类高亲和力的单克隆抗体，可中和IL-33，也有可能用于广泛的适应症。。

“Introducing Zura Bio’s ZB-168 and ZB-880 at World Allergy Congress is an opportunity to share the unique science behind these assets. ZB-168 uniquely inhibits both IL-7 and TSLP, while ZB-880 prevents IL-33 mediated-activation of ST2-dependent and independent inflammation. The unique biology of our assets may give us access to a broad range of biology applicable in a number of autoimmune and inflammatory diseases,” said Michael Howell, Ph.D., Chief Scientific Officer and Head of Translational Science at Zura Bio.

“在世界变态反应大会上介绍Zura Bio的ZB-168和ZB-880是分享这些资产背后独特科学的机会.ZB-168独特地抑制IL-7和TSLP，而ZB-880阻止IL-33介导的激活ST2依赖性和独立性炎症。我们资产的独特生物学可以让我们获得适用于多种自身免疫和Zura Bio的首席科学官兼转化科学负责人Michael Howell博士说。

“We believe these could have applicability in the dermatological, rheumatological, gastrointestinal and respiratory spaces, and we are very excited about taking these development programs forward.”.

“我们相信这些可能适用于皮肤病，风湿病，胃肠道和呼吸系统空间，我们对推进这些发展计划非常兴奋。”。

Details are as follows:

详情如下：

Abstract: WAC23-0180

摘要：WAC23-0180

Title: Biomarker analysis identifies subset of atopic dermatitis patients that respond to IL-33 blockade

题目：生物标志物分析确定了对IL-33阻断有反应的特应性皮炎患者的子集

Authors: Michael Howell, Ph.D., Jackson Cabell, Brandon Walsh, Ph.D., Someit Sidhu, M.D., Christopher Cabell, M.D.

作者：Michael Howell博士，Jackson Cabell博士，Brandon Walsh博士，Someit Sidhu博士，Christopher Cabell博士。

Abstract: WAC23-0179

摘要：WAC23-0179

Title: ZB-168 potently inhibits thymic stromal lymphopoietin mediated Inflammation

题目：ZB-168有效抑制胸腺基质淋巴细胞生成素介导的炎症

Authors: Christopher Cabell, M.D., Javier Cote-Sierra, Ph.D., Karl Deacon, Ph.D., Someit Sidhu, M.D., Michael Howell, Ph.D.

作者：Christopher Cabell，医学博士，Javier Cote Sierra博士，Karl Deacon博士，Someit Sidhu博士，Michael Howell博士。

Full session details can be accessed via the WAC program.

可以通过WAC程序访问完整的会话详细信息。

ABOUT ZURA BIO

关于年龄

Zura Bio is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders. Currently, Zura Bio is developing three assets which have completed Phase 1/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for ZB-106 (tibulizumab), ZB-168, and ZB-880 (torudokimab) with a goal of demonstrating their efficacy, safety, and dosing convenience in immune and inflammatory disorders, including systemic sclerosis, hidradenitis suppurativa, and other novel indications with unmet needs..

Zura Bio是一家多资产临床阶段生物技术公司，专注于开发用于免疫和炎症性疾病的新药。目前，Zura Bio正在开发三项资产，这些资产已完成1/1b期研究并已准备好2期。该公司正在开发ZB-106（tibulizumab），ZB-168和ZB-880（torudokimab）的治疗适应症组合，旨在证明其在免疫和炎症性疾病（包括系统性疾病）中的功效，安全性和剂量便利性。硬化症，化脓性汗腺炎和其他未满足需求的新适应症。。

ABOUT ZB-106 (tibulizumab)

关于ZB-106（tibulizumab）

ZB-106 (tibulizumab) is a potential first-in-class, anti-IL-17 and anti-BAFF dual antagonist that Zura Bio plans to develop for the treatment of systemic sclerosis and hidradenitis suppurativa. ZB-106 is an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of Taltz® (ixekizumab) and tabalumab that neutralizes IL-17A and BAFF.

ZB-106（tibulizumab）是Zura Bio计划开发用于治疗系统性硬化症和化脓性汗腺炎的潜在一流的抗IL-17和抗BAFF双重拮抗剂。ZB-106是通过（ixekizumab）和中和IL-17A和BAFF的tabalumab融合而工程化的IgG scFv双特异性双重拮抗剂抗体。

ZB-106 has been assessed in two Phase 1b studies completed in rheumatoid arthritis and Sjögren's syndrome. The safety profile to date appears to be acceptable, with no new findings relative to known IL-17 and BAFF inhibitors. Chronic toxicology studies have been completed with no adverse drug-related findings.

ZB-106已经在类风湿性关节炎和干燥综合征完成的两项1b期研究中进行了评估。迄今为止的安全性似乎是可以接受的，相对于已知的IL-17和BAFF抑制剂没有新的发现。慢性毒理学研究已经完成，没有药物相关的不良反应。

Phase 2 clinical trials of ZB-106 in systemic sclerosis and hidradenitis suppurativa are planned to initiate 2H-2024..

ZB-106在系统性硬化症和化脓性汗腺炎中的2期临床试验计划于2H-2024启动。。

ABOUT ZB-168

关于ZB-168

ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain (“IL-7R”) alpha. IL-7Rα sits at the nexus of two key immune pathways (IL-7 and TSLP), thus inhibiting IL-7Rα has the potential to block activation through both of these pathways. As a result, we believe ZB-168 could be therapeutically beneficial in a broad set of indications where the IL-7 or TSLP pathways may be involved.

ZB-168是一种完全人类，高亲和力的单克隆抗体，可结合并中和IL-7受体链（“IL-7R”）α。IL-7Rα位于两个关键免疫途径（IL-7和TSLP）的连接处，因此抑制IL-7Rα有可能通过这两种途径阻断激活。因此，我们相信ZB-168可能在涉及IL-7或TSLP途径的广泛适应症中具有治疗益处。

ZB-168 has been assessed in Phase 1/1b clinical studies in Type 1 diabetes and multiple sclerosis. Safety and pharmacokinetics were evaluated and the safety profiles from these studies support further development. A Phase 2 clinical trial of ZB-168 in alopecia areata is planned to initiate in 2024..

ZB-168已在1型糖尿病和多发性硬化症的1/1b期临床研究中进行了评估。评估安全性和药代动力学，这些研究的安全性支持进一步发展。ZB-168在斑秃中的2期临床试验计划于2024年启动。。

FORWARD-LOOKING STATEMENTS

前瞻性声明

This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believe,” “predict,” “potential,” “continue,” “strategy,” “future,” “opportunity,” “would,” “seem,” “seek,” “outlook” and similar expressions are intended to identify such forward-looking statements.

本通讯包括1995年“私人证券诉讼改革法”的“安全港”规定含义内的“前瞻性陈述”。诸如“期待”、“估计”、“项目”、“预算”、“预测”、“期待”、“打算”、“计划”、“五月”、“将会”、“应该”、“相信”、“预测”、“潜力”、“继续”、“战略”、“未来”、“机会”、“将会”、“寻求”、“展望”等词语旨在识别这些表述前瞻性声明。

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties that could cause the actual results to differ materially from the expected results. These statements are based on various assumptions, whether or not identified in this communication.

前瞻性陈述是基于当前预期和假设的关于未来事件的预测，预测和其他陈述，因此可能会导致实际结果与预期结果大不相同的风险和不确定性。这些陈述基于各种假设，无论本通信中是否确定。

These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability..

这些前瞻性陈述仅用于说明目的，并不打算作为投资者的保证，保证，预测或对事实或概率的明确陈述，也不得作为投资者的依赖。。

Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. You should carefully consider the risks and uncertainties described in the “Risk Factors” sections of Zura Bio’s recent filings with the SEC. These filings would identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.

实际事件和情况很难或不可能预测，并且与假设不同。您应该仔细考虑Zura Bio最近向SEC提交的文件“风险因素”部分中描述的风险和不确定性。这些文件将确定并解决可能导致实际事件和结果与所包含的重大事件和结果大不相同的其他重要风险和不确定性在前瞻性声明中。

Many of these factors are outside Zura Bio’s control and are difficult to predict. Many factors could cause actual future events to differ from the forward-looking statements in this communication, including but not limited to: (1) the outcome of any legal proceedings that may be instituted against Zura Bio; (2) volatility in the price of Zura Bio’s securities; (3) the ability of Zura Bio to successfully conduct research and development activities, grow and manage growth profitably, maintain relationships with customers and suppliers, and retain key employees; (4) the ongoing costs relating to operating as a public company; (5) changes in the applicable laws or regulations; (6) the possibility that Zura Bio may be adversely affected by other economic, business, and/or competitive factors; (7) the risk of downturns and a changing regulatory landscape in the highly competitive industry in which Zura Bio operates; (8) the potential inability of Zura Bio to raise additional capital needed to pursue its business objectives or to achieve efficiencies regarding other costs; (9) the enforceability of Zura Bio’s intellectual property, including its patents, and the potential infringement on the intellectual property rights of others, cyber security risks or potential breaches of data security; and (10) other risks and uncertainties describ.

其中许多因素超出了Zura Bio的控制范围，难以预测。许多因素可能导致实际的未来事件与本通信中的前瞻性陈述不同，包括但不限于：（1）可能针对Zura Bio提起的任何法律诉讼的结果；（2） Zura Bio证券价格波动；（3） Zura Bio能够成功开展研发活动，有利地增长和管理增长，与客户和供应商保持关系，留住关键员工；（4） 与经营上市公司有关的持续成本；（5） 适用法律法规的变更；（6） Zura Bio可能受到其他经济，商业和/或竞争因素的不利影响；（7） Zura Bio经营竞争激烈的行业面临挫折的风险和不断变化的监管格局；（8） Zura Bio可能无法筹集实现其业务目标或实现其他成本效率所需的额外资金；（9） Zura Bio知识产权的可执行性，包括其专利，可能侵犯他人的知识产权，网络安全风险或可能违反数据安全；（10）描述其他风险和不确定性。